A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol) | BMC Cancer | Full Text

A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol) | BMC Cancer | Full Text

A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)

Paclitaxel is a standard of care for patients with primary cutaneous angiosarcoma of the scalp and face. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established. ...

Authors:Kohei Oashi, Taro Shibata, Kenjiro Namikawa, Akira Takahashi, Kenji Yokota, Eiji Nakano, Yukiko Teramoto, Arata Tsutsumida, Taku Maeda and Naoya Yamazaki

Citation:BMC Cancer 2020 20:652

Content type:Study protocol

 

Published on: 13 July 2020

• ViewFull Text
 
• ViewPDF